Skip to content

20-074 - A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

Status: open

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma

Treatment for Liver Cancer

Contact Us Or call (251) 445-9834

Description

This clinical trial is for patients who have been diagnosed with Locoregional Hepatocellular Carcinoma (HCC). The study evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy.

Sponsors

This trial is sponsored by Astra Zeneca.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

    This link will open in a new tab or window.